Elisa A. Rozeman

12.9k total citations · 3 hit papers
65 papers, 3.0k citations indexed

About

Elisa A. Rozeman is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Elisa A. Rozeman has authored 65 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 28 papers in Molecular Biology and 25 papers in Immunology. Recurrent topics in Elisa A. Rozeman's work include Cancer Immunotherapy and Biomarkers (51 papers), CAR-T cell therapy research (33 papers) and Melanoma and MAPK Pathways (23 papers). Elisa A. Rozeman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (51 papers), CAR-T cell therapy research (33 papers) and Melanoma and MAPK Pathways (23 papers). Elisa A. Rozeman collaborates with scholars based in Netherlands, Australia and United States. Elisa A. Rozeman's co-authors include Christian U. Blank, John B.A.G. Haanen, Ton N. Schumacher, Hugo M. Horlings, Alexander C. J. van Akkooi, Ido Yofe, Marlous van den Braber, Hanjie Li, Akhiad Bercovich and Yael Baran and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Elisa A. Rozeman

63 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

2018 659 citations Hanjie Li, Anne M. van der Leun et al. Cell profile →
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

2017 504 citations Riccardo Mezzadra, Chong Sun et al. Nature profile →
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

2019 372 citations Maartje W. Rohaan, Elisa A. Rozeman et al. Annals of Oncology profile →

Peers

Elisa A. Rozeman

ONCOL

IMMUN

PRM

RNMI

Sofia R. Gameiro United States

Alexandra Snyder United States

Yvonne M. Saenger United States

Marco de Bruyn Netherlands

Joe Yeong Singapore

Edwin R. Parra United States

Josep M. Piulats Spain

Alexander N. Shoushtari United States

Simon J. Dovedi United Kingdom

Christoph Schliemann Germany

Sofia R. Gameiro United States

Elisa A. Rozeman

1.9k ×0.9

ONCOL

1.5k ×1.2

IMMUN

609 ×0.6

556 ×1.4

PRM

296 ×0.8

RNMI

Citations per year, relative to Elisa A. Rozeman Elisa A. Rozeman (= 1×) peers Sofia R. Gameiro

Countries citing papers authored by Elisa A. Rozeman

Since Specialization

Citations

This map shows the geographic impact of Elisa A. Rozeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa A. Rozeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa A. Rozeman more than expected).

Fields of papers citing papers by Elisa A. Rozeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa A. Rozeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa A. Rozeman. The network helps show where Elisa A. Rozeman may publish in the future.

Co-authorship network of co-authors of Elisa A. Rozeman

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa A. Rozeman. A scholar is included among the top collaborators of Elisa A. Rozeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa A. Rozeman. Elisa A. Rozeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoefsmit, Esmée P., Disha Rao, Petros Dimitriadis, et al.. (2023). Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells. Cancer Immunology Research. 11(4). 450–465. 10 indexed citations

Rozeman, Elisa A., Judith M. Versluis, Alexander M. Menzies, et al.. (2023). 1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma. Annals of Oncology. 34. S660–S661. 1 indexed citations

Versluis, Judith M., et al.. (2023). Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nature Reviews Clinical Oncology. 20(6). 408–422. 22 indexed citations

Gangaev, Anastasia, Elisa A. Rozeman, Maartje W. Rohaan, et al.. (2021). Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proceedings of the National Academy of Sciences. 118(43). 21 indexed citations

Krijgsman, Oscar, Kristel Kemper, Julia Boshuizen, et al.. (2021). Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4. Clinical Cancer Research. 27(19). 5389–5400. 3 indexed citations

Versluis, Judith M., Irene L. M. Reijers, Elisa A. Rozeman, et al.. (2021). Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. European Journal of Cancer. 148. 51–57. 14 indexed citations

Boshuizen, Julia, David W. Vredevoogd, Oscar Krijgsman, et al.. (2020). Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nature Communications. 11(1). 3946–3946. 66 indexed citations

Reijers, Irene L. M., Elisa A. Rozeman, Sofie Wilgenhof, et al.. (2019). Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma. Pigment Cell & Melanoma Research. 33(3). 498–506. 9 indexed citations

Hoefsmit, Esmée P., Elisa A. Rozeman, John B.A.G. Haanen, & Christian U. Blank. (2019). Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open. 4(4). e000472–e000472. 28 indexed citations

10.

Menzies, Alexander M., Elisa A. Rozeman, Rodabe Navroze Amaria, et al.. (2019). Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. Journal of Clinical Oncology. 37(15_suppl). 9503–9503. 63 indexed citations

11.

Moel, Emma C. de, Elisa A. Rozeman, Ellen Kapiteijn, et al.. (2018). Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research. 7(1). 6–11. 129 indexed citations

12.

Foppen, Marnix H. Geukes, Elisa A. Rozeman, Sandra van Wilpe, et al.. (2018). Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 3(1). e000278–e000278. 199 indexed citations

13.

Blank, Christian U., Elisa A. Rozeman, Alexander M. Menzies, et al.. (2018). OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). Annals of Oncology. 29. viii734–viii734. 12 indexed citations

14.

Li, Hanjie, Anne M. van der Leun, Ido Yofe, et al.. (2018). Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell. 176(4). 775–789.e18. 659 indexed citations breakdown →

15.

Rozeman, Elisa A., Tim Dekker, John B.A.G. Haanen, & Christian U. Blank. (2017). Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. American Journal of Clinical Dermatology. 19(3). 303–317. 78 indexed citations

16.

Rozeman, Elisa A., Lorenzo F. Fanchi, Alexander C. J. van Akkooi, et al.. (2017). (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses. Annals of Oncology. 28. v432–v432. 10 indexed citations

17.

Mezzadra, Riccardo, Chong Sun, Lucas T. Jae, et al.. (2017). Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 549(7670). 106–110. 504 indexed citations breakdown →

18.

Rozeman, Elisa A., Jules Gadiot, Marnix H. Geukes Foppen, et al.. (2017). Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial). Annals of Oncology. 28. v446–v446. 3 indexed citations

19.

Jansen, Yanina, Elisa A. Rozeman, Marnix Geukes Foppen, et al.. (2016). Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). Annals of Oncology. 27. vi386–vi386. 4 indexed citations

20.

Akkooi, Alexander C. J. van, Elisa A. Rozeman, Pia Kvistborg, et al.. (2016). (Neo-)adjuvant ipilimumab + nivolumab (IPI + NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial. Annals of Oncology. 27. vi575–vi575. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact